Calcium antagonists are a heterogeneous group of drugs, however, even beyond the usual dichotomization to dihydropyridine and nondihydropyridine agents. Their effects on both ortho‐static hypotension and sedation are potentiated by ethanol and other central nervous system depressants. In addition, withdrawal from heroin or nicotine acutely raises BP.There are 4 major types of steroids that raise BP: anabolic steroids, corticosteroids, mineralocorticoids and estrogenic steroids.
Perhaps most convincingly, two head‐to‐head clinical trials comparing celecoxib (200 mg/d) and rofecoxib (25 mg/d) in 1894 hypertensive patients with osteoarthritis showed a lower frequency of significant elevation of systolic blood pressure (the primary end point, defined as systolic BP ≥140 mm Hg and an increase >20 mm Hg compared with baseline) with celecoxib in both trials (Figure 1). Many combinations of a diuretic and another antihypertensive drug have been approved for marketing by the US Food and Drug Administration (FDA) and have become quite commercially successful.Thiazide and thiazide‐like diuretics can potentiate the effects of nondepolarizing muscle relaxants and antagonize norepinephrine.

Likewise, propranolol potentiates the effects of many other drugs, including amiodarone, chlorpromazine, diazepam, lidocaine, propafenone, rizatriptan, theophylline, thioridazine, warfarin, and zolmitriptan.These two classes of antihypertensive drugs share their propensity to be adversely affected (for BP control, fluid retention, and renal dysfunction) by NSAIDs. If you want to know all the information, more than what the Dr. and Pharmacist will tell you, just got to Seroquel.com and Depakote.com. Although there was initial hope that tacrolimus (also known in the older literature as FK‐506) would avoid this adverse effect, at least in liver transplant recipients, there appears to be little difference between tacrolimus and cyclosporine in either hypertension incidence or nephrotoxicity.The mechanism(s) of these effects is/are complex and may be related to binding of either drug to calcineurin, a calcium‐calmodulin‐dependent phosphatase. Prednisone is a synthetic corticosteroid that reduces inflammation and suppresses the immune system. In obese but normotensive subjects in placebo‐controlled trials, it increased BP by about 3/2 mm Hg and pulse rate by 4.9 bpm; however, 5.3% became hypertensive (vs 1.4% on placebo). Cimetidine and cyclosporine have substantive interactions with most calcium antagonists; the latter's interaction with diltiazem has been used to reduce the dose of expensive cyclosporine in some centers. By continuing to browse this site, you agree to its use of cookies as described in our I have read and accept the Wiley Online Library Terms and Conditions of UseAntihypertensive therapy: special focus on drug interactionsHigh blood pressure: a side‐effect of drugs, poisons, and foodHerbs and alternative therapies: relevance to hypertension and cardiovascular diseases11β‐Hydroxysteroid dehydrogenase and the pre‐receptor regulation of corticosteroid hormone actionEffects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitorsEffects of celecoxib on cardiorenal adverse events: meta‐analysis of 41 clinical trials in over 44,000 patients [abstract]Meta‐analysis of cyclooxygenase‐2 inhibitors and their effects on blood pressureCyclooxygenase‐2‐specific inhibitors and cardiorenal function: a randomized controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients [published correction appears in Am J Ther 2001;8:220]Effects of celecoxib and rofecoxib on blood pressure and edema in patients >or =65 years of age with systemic hypertension and osteoarthritisInfluence of sibutramine on blood pressure: evidence from placebo‐controlled trialsCyclosporine‐induced hypertension: incidence, pathogenesis and managementTherapeutic exercise for hypertension: An update for exercise prescribers, Validity of Self-reported Hypertension and Factors Related to Discordance Between Self-reported and Objectively Measured Hypertension: Evidence From a Cohort Study in Iran, The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019), Secondary Hypertension: Infrequently Considered Aspects—Illicit/Recreational Substances, Herbal Remedies, and Drug-Associated Hypertension, Arterielle Hypertonie im Alter mit dem Fokus 80+Arterial hypertension in old age with the focus on 80+, KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors, PK/PD modeling of β-blockers in cardiovascular disease: an update, Common Substances That May Contribute to Resistant Hypertension, and Recommendations for Limiting Their Clinical Effects, Drug-induced blood pressure increase – recommendations for assessment in clinical and non-clinical studies, Incidence, aetiology and mortality secondary to hypertensive emergencies in a large-scale referral centre in Israel (1991–2010), Drug induced hypertension – An unappreciated cause of secondary hypertension, Transient severe hypotension with once-weekly subcutaneous injection of teriparatide in osteoporotic patient: a case report and insight for the drug interaction between hypotensive agents and teriparatide, Nonsteroidal anti-inflammatory drugs and antihypertensives: how do they relate?, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Relevancia clínica de las interacciones medicamentosas entre antiinflamatorios no esteroideos y antihipertensivos, Hypertension: A Companion to Braunwald’s Heart Disease, Hypertension: A Companion to Braunwald’s Heart Disease, Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium, Polypharmacy and the Role of Physical Medicine and Rehabilitation, Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension, Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations, Preventive Cardiology: Companion to Braunwald's Heart Disease, Pathway analysis of seven common diseases assessed by genome-wide association, Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor,